CHICAGO (Reuters) - Scientists have characterized the role of thousands of mutations in the BRCA2 cancer gene, findings that ...

Findings from a multi-institutional, international study have significantly advanced the understanding of genetic alterations in the BRCA2 gene, a key player in hereditary cancer risk.

"I just wish someone had told me this was a possibility." Kara Maxwell distinctly remembers the moment she heard those words ...

Around 1,200 people with advanced breast cancer could benefit from a decision by NICE to give the go-ahead to a new treatment ...

Findings from a multi-institutional, international study led by researchers from the Mayo Clinic Comprehensive Cancer Center ...

Scientists have taken a significant step in understanding mutations in the BRCA2 gene, associated with increased cancer risk, ...

Recent studies have identified risks in BRCA2 gene mutations, leading to better cancer risk assessment and treatment. Other ...

Recent health updates see UnitedHealth shareholders challenging healthcare denial impacts. BRCA2 cancer gene mutation risks ...

The National Institute for Health and Care Excellence (NICE) has given a positive recommendation for Lynparza (olaparib) for ...

Testing BRCA2 has long been a staple of hereditary cancer testing, as pathogenic variants in the gene are associated with cancers of the breast, ovary, prostate, and pancreas. 2-5 Despite the ...

Mr. Knowles is opening up about something else near and dear to his heart — his experience as a male breast cancer survivor ...

Findings from a multi-institutional, international study led by researchers from the Mayo Clinic Comprehensive Cancer Center ...